Sugi Predict

Sugi Predict / Compounds / SCHEMBL397335

SCHEMBL397335

SCHEMBL397335

Nc1ncnc2c1c(I)cn2C1CC(CO)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 4/20 0.59
▸ ABL1 P00519 3/20 0.59
▸ RET P07949 2/20 0.59
▸ JAK2 O60674 1/20 0.59
▸ NTRK1 P04629 1/20 0.59
▸ INSR P06213 1/20 0.59
▸ LCK P06239 1/20 0.59
▸ NPM1 P06748 1/20 0.59
▸ CSF1R P07333 1/20 0.59
▸ LYN P07948 1/20 0.59
▸ IGF1R P08069 1/20 0.59
▸ MET P08581 1/20 0.59
▸ PDGFRB P09619 1/20 0.59
▸ KIT P10721 1/20 0.59
▸ BCR P11274 1/20 0.59
▸ FGFR1 P11362 1/20 0.59
▸ PDGFRA P16234 1/20 0.59
▸ FLT1 P17948 1/20 0.59
▸ FGFR2 P21802 1/20 0.59
▸ FGFR4 P22455 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL400703 1.00 SRC (0.59) SRCABL1RETJAK2NTRK1
SCHEMBL397336 1.00 SRC (0.59) SRCABL1RETJAK2NTRK1
SCHEMBL9951321 0.88 SRC (0.53) SRCABL1RETJAK2NTRK1
SCHEMBL1442499 0.88 SRC (0.53) SRCABL1RETJAK2NTRK1
SCHEMBL1933032 0.88 MTOR (0.55) SRCABL1RETJAK2NTRK1
SCHEMBL13721084 0.88 MTOR (0.55) SRCABL1RETJAK2NTRK1
SCHEMBL18297551 0.85 MTOR (0.56) SRCABL1RETJAK2NTRK1
SCHEMBL18589194 0.85 MTOR (0.56) SRCABL1RETJAK2NTRK1
SCHEMBL398110 0.84 ADK (0.57) SRCABL1RETJAK2NTRK1
SCHEMBL398720 0.84 ADK (0.57) SRCABL1RETJAK2NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168968-B1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS LLC (US) 2017-08-23 — — EP disclosed
US-8735405-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-05-27 — — US disclosed
US-8653268-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-02-18 — — US disclosed
EP-2683722-A1 FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS Novartis AG (CH) 2014-01-15 — — EP disclosed
US-20130338152-A1 FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS IRM LLC (BM) 2013-12-19 — — US disclosed
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2013-07-25 — — US disclosed
US-8367826-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2013-02-05 — — US disclosed
US-20120289501-A1 Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls NOVARTIS AG (CH) 2012-11-15 — — US disclosed
EP-2504339-A1 BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS Novartis AG (CH) 2012-10-03 — — EP disclosed
WO-2012120469-A1 FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS NOVARTIS AG (CH) 2012-09-13 — — WO disclosed
EP-2308879-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2011-04-13 — — EP disclosed
EP-2305682-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2011-04-06 — — EP disclosed
WO-2011029915-A1 ETHER DERIVATIVES OF BICYCLIC HETEROARYLS NOVARTIS AG (CH) 2011-03-17 — — WO disclosed
US-7820662-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-10-26 — — US disclosed
EP-2168968-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2010-03-31 — — EP disclosed
EP-2168968-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2010-03-31 — — EP disclosed
US-20090325928-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-12-31 — — US disclosed
US-7534797-B2 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-05-19 — — US disclosed
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338152-A1 FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS IGF1R, IGFBP1, IGFBP2 SRC 870/4885ABL1 208/4885RET 693/4885
US-20120289501-A1 Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls CYP1B1, CYP11B2, CCNI SRC 660/4885ABL1 154/4885RET 1157/4885
US-20090325928-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885ABL1 621/4885RET 686/4885
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885ABL1 621/4885RET 686/4885
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885ABL1 621/4885RET 686/4885
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885ABL1 621/4885RET 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.